NASDAQ:SYBX

Synlogic Stock Forecast, Price & News

$3.52

+0.26 (+7.98 %)

(As of 01/15/2021 12:00 AM ET)

Add

Compare

Today's Range

$3.16

Now: $3.52▼

$3.57

50-Day Range

$2.11

MA: $2.33▼

$3.26

52-Week Range

$1.35

Now: $3.52▼

$3.99

Volume1.55 million shs

Average Volume4.48 million shs

Market Capitalization$122.62 million

P/E RatioN/A

Dividend YieldN/A

Beta2.12

Synlogic, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its therapeutic programs include SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with Ginkgo Bioworks for the development of synthetic biotic medicines. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.

MarketRank^™

Overall MarketRank^™

1.62 out of 5 stars

3.3 Analyst's Opinion

Consensus Rating
Synlogic has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $11.50, Synlogic has a forecasted upside of 226.7% from its current price of $3.52.
Amount of Analyst Coverage
Synlogic has only been the subject of 1 research reports in the past 90 days.

2.7 Community Rank

Outperform Votes
Synlogic has received 299 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Synlogic has received 251 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Synlogic has received 54.36% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Synlogic and other stocks. Vote “Outperform” if you believe SYBX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SYBX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Synlogic does not currently pay a dividend.
Dividend Growth
Synlogic does not have a long track record of dividend growth.

0.8 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Synlogic insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 17.95% of the stock of Synlogic is held by insiders.
Percentage Held by Institutions
44.18% of the stock of Synlogic is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3 Earnings and Valuation

Earnings Growth
Earnings for Synlogic are expected to grow in the coming year, from ($1.84) to ($1.64) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Synlogic is -2.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Synlogic is -2.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Synlogic has a P/B Ratio of 0.72. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:SYBX

Previous Symbol

CUSIPN/A

CIK1527599

Webwww.synlogictx.com

Phone617-401-9975

Employees76

Debt

Debt-to-Equity RatioN/A

Current Ratio20.18

Quick Ratio20.18

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$2.22 million

Price / Sales55.23

Cash FlowN/A

Price / Cash FlowN/A

Book Value$4.86 per share

Price / Book0.72

Profitability

EPS (Most Recent Fiscal Year)($1.70)

Net Income$-51,370,000.00

Net Margins-2,761.83%

Return on Equity-38.34%

Return on Assets-31.85%

Miscellaneous

Outstanding Shares34,834,000

Market Cap$122.62 million

Next Earnings Date3/11/2021 (Estimated)

OptionableNot Optionable

$3.52

+0.26 (+7.98 %)

(As of 01/15/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive SYBX News and Ratings via Email

Sign-up to receive the latest news and ratings for SYBX and its competitors with MarketBeat's FREE daily newsletter.

Synlogic (NASDAQ:SYBX) Frequently Asked Questions

How has Synlogic's stock been impacted by COVID-19?

Synlogic's stock was trading at $1.54 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, SYBX shares have increased by 128.6% and is now trading at $3.52.
View which stocks have been most impacted by COVID-19.

Is Synlogic a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Synlogic in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Synlogic stock.
View analyst ratings for Synlogic or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Synlogic?

Wall Street analysts have given Synlogic a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Synlogic wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Synlogic's next earnings date?

Synlogic is scheduled to release its next quarterly earnings announcement on Thursday, March 11th 2021.
View our earnings forecast for Synlogic.

How were Synlogic's earnings last quarter?

Synlogic, Inc. (NASDAQ:SYBX) posted its quarterly earnings results on Thursday, November, 5th. The biotechnology company reported ($0.36) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.47) by $0.11. Synlogic had a negative net margin of 2,761.83% and a negative return on equity of 38.34%.
View Synlogic's earnings history.

When did Synlogic's stock split? How did Synlogic's stock split work?

Shares of Synlogic reverse split on Monday, August 28th 2017. The 1-7 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 25th 2017. An investor that had 100 shares of Synlogic stock prior to the reverse split would have 14 shares after the split.

What price target have analysts set for SYBX?

3 equities research analysts have issued 12 month target prices for Synlogic's stock. Their forecasts range from $10.00 to $13.00. On average, they expect Synlogic's share price to reach $11.50 in the next year. This suggests a possible upside of 226.7% from the stock's current price.
View analysts' price targets for Synlogic or view Wall Street analyst' top-rated stocks.

Are investors shorting Synlogic?

Synlogic saw a drop in short interest in the month of December. As of December 31st, there was short interest totaling 363,200 shares, a drop of 64.0% from the December 15th total of 1,010,000 shares. Based on an average daily volume of 1,090,000 shares, the short-interest ratio is presently 0.3 days. Approximately 1.8% of the shares of the stock are sold short.
View Synlogic's Short Interest.

Who are some of Synlogic's key competitors?

Some companies that are related to Synlogic include IDEAYA Biosciences (IDYA), XBiotech (XBIT), Bicycle Therapeutics (BCYC), resTORbio (TORC), Viking Therapeutics (VKTX), Mirum Pharmaceuticals (MIRM), Crinetics Pharmaceuticals (CRNX), Amryt Pharma (AMYT), Spero Therapeutics (SPRO), Wave Life Sciences (WVE), Nabriva Therapeutics (NBRV), Orphazyme A/S (ORPH), Akebia Therapeutics (AKBA), XOMA (XOMA) and Summit Therapeutics (SMMT).
View all of SYBX's competitors.

What other stocks do shareholders of Synlogic own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Synlogic investors own include Reata Pharmaceuticals (RETA), Approach Resources (AREX), Precision Drilling (PDS), First Financial Bankshares (FFIN), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Corbus Pharmaceuticals (CRBP), Inovio Pharmaceuticals (INO), Rigel Pharmaceuticals (RIGL) and Verastem (VSTM).

Who are Synlogic's key executives?

Synlogic's management team includes the following people:

Dr. Aoife M. Brennan M.D., MB, BCh, BAO, MMSc, Pres, CEO & Director (Age 45, Pay $737.3k)
Dr. Richard J. Riese M.D., Ph.D., Chief Medical Officer (Age 58, Pay $209.16k)
Prof. Timothy K. Lu, Co-Founder
Dr. James J. Collins, Co-Founder (Age 55)
Mr. Antoine Awad, Chief Operating Officer
Mr. Daniel Rosan, Head of Corp. Fin. & Investor Relations
Dr. David L. Hava, Chief Scientific Officer (Age 46)
Dr. Elizabeth Wolffe, Head of Investor Relations & Corp. Communications
Mr. Adam Thomas, Chief People Officer & Sec.
Dr. Caroline B. Kurtz Ph.D., Head of Translational Sciences & Product Devel.

What is Synlogic's stock symbol?

Synlogic trades on the NASDAQ under the ticker symbol "SYBX."

How do I buy shares of Synlogic?

Shares of SYBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Synlogic's stock price today?

One share of SYBX stock can currently be purchased for approximately $3.52.

How big of a company is Synlogic?

Synlogic has a market capitalization of $122.62 million and generates $2.22 million in revenue each year. The biotechnology company earns $-51,370,000.00 in net income (profit) each year or ($1.70) on an earnings per share basis. Synlogic employs 76 workers across the globe.

What is Synlogic's official website?

The official website for Synlogic is www.synlogictx.com.

How can I contact Synlogic?

Synlogic's mailing address is 301 Binney St. Suite 402, Cambridge MA, 02142. The biotechnology company can be reached via phone at 617-401-9975 or via email at [email protected]

This page was last updated on 1/18/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here